Research and Markets: Sickle Cell Anemia Therapeutics Market is Forecast to Show Slow Growth Until 2018

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/d296d3/sickle_cell_anemia) has announced the addition of GlobalData's new report "Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

“Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”

GlobalData, the industry analysis specialist, has released its new report, Sickle Cell Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Sickle Cell Anemia Therapeutics market. The report identifies the key trends shaping and driving the global Sickle Cell Anemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Sickle Cell Anemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Sickle Cell Anemia Therapeutics Market is Forecast to Show Slow Growth Until 2018

GlobalData valued the global (to include the US, the UK, France, Germany, Italy, Spain and Japan) Sickle Cell Anemia therapeutics market at $33m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 18.9% to reach $130m in 2018. There are no approved branded drugs in the sickle cell anemia market. The Phase II pipeline has two potential novel molecules GMI-1070 (orphan drug and fast track status by US Food and Drug Administration (FDA)) and HQK-1001 (orphan drug in the US and Europe).These drugs are expected to be launched in the forecast period. GMI-1070 is expected to replace the use of hydroxyurea in adolescents and adults in the near future. However, the market is expected to have slow growth until 2018.

Key Topics Covered:

• List of Tables and Figures
• Sickle Cell Anemia Therapeutics - Introduction
• Sickle Cell Anemia Therapeutics - Market Characterization
• Sickle Cell Anemia Therapeutics Market - Competitive Assessment
• Sickle Cell Anemia Therapeutics - Pipeline Assessment
• Sickle Cell Anemia Therapeutics - Clinical Trials Mapping
• Sickle Cell Anemia Therapeutics - Strategic Assessment
• Sickle Cell Anemia Therapeutics - Future Players
• Sickle Cell Anemia Therapeutics - Licensing and Partnership Deals
• Sickle Cell Anemia Therapeutics - Appendix

Companies Mentioned:

• Anthera Pharmaceuticals Inc. (Anthera)
• Novartis Pharmaceuticals
• GlycoMimetics, Inc.
• Pfizer
• HemaQuest Pharmaceuticals Inc.

For more information visit http://www.researchandmarkets.com/research/d296d3/sickle_cell_anemia